Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature

J Chemother. 2015 Oct;27(5):307-11. doi: 10.1179/1973947814Y.0000000194. Epub 2014 May 14.


Objectives: To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme.

Case report: We used nebulized liposomal amphotericin B (L-AMB) in a patient affected by CF, complicated by ABPA. The previous combined treatment with oral steroids and azoles had no respiratory benefit and caused relevant side effects. Amphotericin B has always been well tolerated and permitted a slight steroid tapering. We also observed benefits in pulmonary function and laboratory tests.

Conclusions: Few data are available in literature about the use of nebulized AMB in CF and there are no RCTs evaluating antifungals in CF-ABPA. In our opinion, the reported case suggests that nebulized L-AMB could represent a possible strategy in ABPA management in CF patients.

Keywords: Amphotericin B,; Antifungal therapy,; Aspergillosis,; Azole antifungals; Cystic fibrosis,.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / microbiology
  • Aspergillus fumigatus / drug effects*
  • Cystic Fibrosis / complications*
  • Disease Management
  • Humans
  • Male
  • Young Adult


  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B